Our Science

GV1001 is a 16 amino acid peptide synthesized using key sequences of telomerase function.

· GV1001 improves locomotor deficit by reducing tau phosphorylation in the motor cortex of a mouse models of PSP

GV1001 imrpoves memory deficits and glial dysfunction in mouse models of ad.

· GV1001 improves learning and memory deficits by reducing synaptic loss in the hippocampus of a mouse models of AD. · GV1001 reduces Aβ plaque burden and tau aggregation by promoting microglia phagocytosis.

Parkinson's disease (PD, MPTP model)

The MPTP model is one of the most widely used models of neurotoxin Parkinson's disease, characterized by a decrease in the dopamine metabolome (dopamine, DOPAC and HVA) in the striatum and induction of loss of dopaminergic neurons in the substantia nigra. Studies are underway to validate its protective effects on dopaminergic neurons.

Multiple sclerosis (MS, MOG35 - 55 model)

One of the gold standard animal models of multiple sclerosis, experimental autoimmune encephalomyelitis. Using the MOG35 - 55 model, which best reproduces relapsing-remitting multiple sclerosis, the most common type of MS, we are conducting validation studies for demyelinating effects.

Amyotrophic lateral sclerosis (ALS)

We are conducting efficacy validation studies on dyskinesia using models with mutations in genes such as SOD1 and C9orf72, which are known to be representative genes for the development of ALS.